FDA Adds Temporary Expertise To ODAC For Filgrastim Biosimilar Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
NIH researcher of cellular therapy manufacturing, experts in pharmacology and pharmaceutical sciences join Oncologic Drugs Advisory Committee for consideration of FDA’s first 351(k) application.